Latest news with #Long-TermIncentivePlan
Cision Canada
2 days ago
- Business
- Cision Canada
Minco Silver Announces Grant of Stock Options
VANCOUVER, BC, June 6, 2025 /CNW/ - Minco Silver Corporation (the "Company") announces that its Board of Directors has approved the grant of an aggregate of 2,900,000 incentive stock options to directors, officers, consultants and employees of the Company, pursuant to the Company's Long-Term Incentive Plan. The stock options are exercisable at a price of $0.21 per common share, being the closing price of the Company's shares on the Toronto Stock Exchange on June 3, 2025. The options will expire five years from the date of grant and are subject to vesting over a period of 18 months, in accordance with the terms of the Company's Long-Term Incentive Plan. The Long-Term Incentive Plan was approved by the Company's shareholders at its Annual General Meeting held on June 28, 2024, and subsequently approved by the Toronto Stock Exchange on July 15, 2024. About Minco Silver Corporation Minco Silver Corporation (TSX: MSV / OTCQX: MISVF / WKN: A0ESX5) is a Canadian-based company focused on the acquisition, exploration, and development of high-grade silver properties. The Company remains committed to building shareholder value through strategic investments and disciplined project evaluation. SOURCE Minco Silver Corporation
Yahoo
2 days ago
- Business
- Yahoo
Minco Silver Announces Grant of Stock Options
TSX: MSV | OTCQX: MISVF | WKN: A0ESX5 VANCOUVER, BC, June 6, 2025 /CNW/ - Minco Silver Corporation (the "Company") announces that its Board of Directors has approved the grant of an aggregate of 2,900,000 incentive stock options to directors, officers, consultants and employees of the Company, pursuant to the Company's Long-Term Incentive Plan. The stock options are exercisable at a price of $0.21 per common share, being the closing price of the Company's shares on the Toronto Stock Exchange on June 3, 2025. The options will expire five years from the date of grant and are subject to vesting over a period of 18 months, in accordance with the terms of the Company's Long-Term Incentive Plan. The Long-Term Incentive Plan was approved by the Company's shareholders at its Annual General Meeting held on June 28, 2024, and subsequently approved by the Toronto Stock Exchange on July 15, 2024. ON BEHALF OF THE BOARD"Ken Cai"CEO About Minco Silver Corporation Minco Silver Corporation (TSX: MSV / OTCQX: MISVF / WKN: A0ESX5) is a Canadian-based company focused on the acquisition, exploration, and development of high-grade silver properties. The Company remains committed to building shareholder value through strategic investments and disciplined project evaluation. SOURCE Minco Silver Corporation View original content:
Yahoo
22-05-2025
- Business
- Yahoo
Launch of Long-Term Incentive Plan for executive management and key employees
COMPANY ANNOUNCEMENT NO 28/2025 – MAY 22, 2025Royal Unibrew A/S launches a new share-based Long-Term Incentive Plan (LTIP) for executive management and selected key employees for 2025. The plan is designed to align the interests of Royal Unibrew's employees and shareholders and to retain employees. The new LTIP for 2025 has been approved by the Board of Directors. The LTIP is based on Performance Share Units (PSU) granted to each key employee. The PSUs are granted in 2025 for vesting on the date the Board of Directors approves and makes public the annual report for 2027. A PSU may vest into one Royal Unibrew A/S share according to the company's performance over the period 2025 to 2027 and the terms of the LTIP. The total number of shares allocated by the company under the LTIP is up to 105,000 shares, of which 40,006 pertain to members of the executive management. The allocation of shares is based on the average closing price for Royal Unibrew A/S' shares on Nasdaq OMX Copenhagen during the first five trading days following the release of the annual report for 2024, which is DKK 549.30 per share (nominal value of DKK 2,00). The KPIs used in the program are a) average organic EBIT growth over the years 2025 to 2027; b) ROIC for calendar year 2027; c) Lost Time Incidents reduction by 2027 compared to 2024; and d) CO2/HL for scope 1, 2 and 3 reduction by 2027 compared to 2024. Each KPI is defined by a maximum and a minimum threshold. If the performance is below the minimum threshold, no PSUs will vest. Performance between the minimum and maximum thresholds will be calculated linearly. No additional PSUs are awarded if the KPI exceeds the maximum threshold. Assuming all KPIs meet their targets, the maximum value at grant is around DKK 58 million, whereas the theoretical market value of the LTIP at the time of grant is around DKK 39 million. These values are based on the average closing share price the five first trading days after publication of the annual report. For further information on this Announcement: Flemming Ole Nielsen (Head of Investor Relations)E-mail: +45 25 41 68 04 Attachment Fond-RU-28-2025-uk-LTIP 2025 _final
Malaysian Reserve
06-05-2025
- Business
- Malaysian Reserve
Cboe Global Markets Announces 2025 Annual Meeting Results
CHICAGO, May 6, 2025 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, today announced the preliminary shareholder voting results from its 2025 Annual Meeting held today. All 12 board of director nominees served during the 2024-2025 board term and received a majority of votes cast. The board members re-elected to serve one-year terms expiring in 2026 are: William M. Farrow, III Fredric J. Tomczyk Edward J. Fitzpatrick Ivan K. Fong Janet P. Froetscher Jill R. Goodman Erin A. Mansfield Cecilia H. Mao Alexander J. Matturri, Jr. Jennifer J. McPeek Roderick A. Palmore James E. Parisi In other proposals, shareholders: Approved, in a non-binding resolution, the compensation paid to the company's executive officers; Ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the 2025 fiscal year; Approved the Third Amended and Restated Cboe Global Markets, Inc. Long-Term Incentive Plan to, among other things, increase the share reserve by 3,000,000 shares and extend the term of the plan; and Approved a stockholder proposal regarding political spending. Additional information about each of the matters acted upon by shareholders at the Annual Meeting is in the proxy statement that was furnished to shareholders in connection with the meeting. The proxy statement is also available in the Investor Relations section of The final vote totals for the matters acted upon by shareholders at the Annual Meeting will be reported in a current report on Form 8-K filing with the SEC and posted on About Cboe Global Markets, Inc. Cboe Global Markets (Cboe: CBOE), the world's leading derivatives and securities exchange network, delivers cutting-edge trading, clearing and investment solutions to people around the world. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives and FX across North America, Europe and Asia Pacific. Above all, we are committed to building a trusted, inclusive global marketplace that enables people to pursue a sustainable financial future. To learn more about the Exchange for the World Stage, visit . Cboe Media Contacts Cboe Analyst Contact Angela Tu Tim Cave Kenneth Hill, CFA +1-646-856-8734 +44 (0) 7593-506-719 +1-312-786-7559 atu@ tcave@ khill@ CBOE-C CBOE-OE Cboe® and Cboe Global Markets® are registered trademarks of Cboe Exchange, Inc. View original content to download multimedia: SOURCE Cboe Global Markets, Inc.
Yahoo
21-03-2025
- Business
- Yahoo
Angle PLC Announces Issue of LTIP Options and Share Options
GUILDFORD, SURREY / / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 11 July 2024 ("the Remuneration Policy"), the Remuneration Committee has approved the grant under the Long-Term Incentive Plan (LTIP) of options (the "LTIP Options") over a maximum of 12,000,000 ordinary shares of £0.10 ("Ordinary Shares"), subject to the performance conditions set out below, to the Company's executive directors. The Remuneration Committee has also approved the issue of up to 13,800,000 share options under its existing share option plans to staff (the "Staff Share Options"). Share options are issued to align the interest of employees with shareholders and help motivate, reward and retain staff. The allocation of LTIP Options and Staff Share Options approved by the Remuneration Committee also takes into account that, for the third consecutive year, no bonuses for executives and staff were awarded in order to help conserve cash and extend the Company's cash runway. While a staff share option award was made in 2024, the allocation for executive directors reflects a catch-up award for 2024 as well as a 2025 award following the agreement to waive cash bonus entitlements for both 2023 and 2024 operating years. Following the issue of these options, the Company will have outstanding options over a total of up to 51,369,480 Ordinary Shares, representing approximately 13.7% of its issued and to be issued share capital, which is within the Remuneration Policy approved limit of up to 16%. The exercise price for the Staff Share Options is 10.00 pence per Ordinary Share, being 2.6% above the Company's closing mid-market share price of 9.75 pence per Ordinary Share on 20 March 2025, being the latest practicable date prior to this announcement. The Staff Share Options are subject to certain service and/or performance conditions over a three-year period. The LTIP Options have performance conditions as set out below, a performance period of three years and an additional holding period of two years. Subject to the rules of the LTIP, awards will vest only to the extent that the performance conditions have been met during the performance period and the underlying shares may only be traded once the holding period is completed. The LTIP Options contain normal "good leaver", "bad leaver" and change of control provisions, and malus and clawback provisions will apply under certain circumstances. The intention of the LTIP is to reward tangible increases in shareholder value, in this case above the share price of the last funding round (15.00 pence per Ordinary Share in June 2024). The performance conditions for the LTIP Options relate to the compound annual growth rate (CAGR) of the share price from this base level over the three-year performance period. As different levels of performance are achieved the number of shares that vest increases up to a maximum as set out below: Allocation of LTIP options Share price CAGR on funding round Multiple of funding round share price Multiple of current share price Proportion vesting Andrew Newland Ian Griffiths Total < 20% < 1.73 <2.66 0% 0 0 0 > 20% > 1.73 >2.66 20% 1,440,000 960,000 2,400,000 > 25% > 1.95 >3.00 50% 3,600,000 2,400,000 6,000,000 > 30% > 2.20 >3.38 100% 7,200,000 4,800,000 12,000,000 The non-executive directors of the Company do not hold share options. As at 20 March 2025, the Company has 322,641,668 Ordinary Shares in issue. The below notification made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Andrew Newland 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification /Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name ANGLE plc b) LEI 213800BY11K6W3NMS374 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Options over Ordinary shares of £0.10 each ISIN: GB0034330679 b) Nature of the transaction Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme c) Price(s) and volume(s) Price(s) Volume(s) Nil Up to 7,200,000 dependent on share price performance d) Aggregated information - Aggregated volume - Price N/A e) Date of the transaction 20 March 2025 f) Place of the transaction Outside a trading venue 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Ian Griffiths 2 Reason for the notification a) Position/status Finance Director b) Initial notification /Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name ANGLE plc b) LEI 213800BY11K6W3NMS374 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Options over Ordinary shares of £0.10 each ISIN: GB0034330679 b) Nature of the transaction Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme c) Price(s) and volume(s) Price(s) Volume(s) Nil Up to 4,800,000 dependent on share price performance d) Aggregated information - Aggregated volume - Price N/A e) Date of the transaction 20 March 2025 f) Place of the transaction Outside a trading venue For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Sign in to access your portfolio
